NASDAQ:CRME TSX:COM
VANCOUVER, Jan. 10, 2018 /PRNewswire/ - Cardiome Pharma
Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty
pharmaceutical company focused on commercializing patent-protected
hospital drugs, today announced that Mr. Justin Renz, Chief Financial Officer of
Cardiome, will participate in a panel discussion at the Cantor
Fitzgerald Antibiotics Summit. The panel, titled "Why New, But More
Expensive Antibiotics Will Get Used," will take place at the Omni
Berkshire on Wednesday, January 17,
2018 at 11:00 a.m. EST.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a revenue-generating, specialty
pharmaceutical company focused on providing innovative,
high-quality brands that meet the needs of acute care physicians
and patients. With a commercial presence and distribution
network covering over 60 countries worldwide, Cardiome develops,
acquires and commercializes brands for the in-hospital, acute care
market segment. The Company's portfolio of approved and
marketed brands includes: Xydalba™ (dalbavancin hydrochloride), for
the treatment of acute bacterial skin and skin structure infections
(ABSSSI); Zevtera®/Mabelio® (ceftobiprole
medocaril sodium), a cephalosporin antibiotic for the treatment of
community- and hospital-acquired pneumonia (CAP, HAP);
Brinavess® (vernakalant IV) for the rapid conversion of
recent onset atrial fibrillation to sinus rhythm;
Aggrastat® (tirofiban hydrochloride) for the reduction
of thrombotic cardiovascular events in patients with acute coronary
syndrome, and Esmocard® and Esmocard Lyo®
(esmolol hydrochloride), a short-acting beta-blocker used to
control rapid heart rate in a number of cardiovascular
indications. Cardiome's pipeline of product candidates
includes Trevyent®, a drug device combination that is
designed to deliver Remodulin® (treprostinil) the
world's leading treatment for pulmonary arterial hypertension.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the
Toronto Stock Exchange (COM). For more information, please visit
our web site at www.cardiome.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 or forward-looking information under
applicable Canadian securities legislation ("forward-looking
statements") that may not be based on historical fact, including
without limitation statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate",
"intend", "expect" and similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. A discussion of the risks and uncertainties
facing Cardiome are discussed in our most recent annual and
quarterly reports and detailed from time to time in our other
filings with the Securities and Exchange Commission ("SEC")
available at www.sec.gov and the Canadian securities regulatory
authorities at www.sedar.com. All of the risks and
certainties disclosed in these filings are hereby incorporated by
reference in their entirety. While Cardiome makes these
forward-looking statements in good faith, given these risks,
uncertainties and factors, you are cautioned not to place undue
reliance on any forward-looking statements made in this press
release. All forward-looking statements made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward-looking statements to reflect subsequent
events or circumstances, except as required by law.
Cardiome® and the Cardiome Logo are the proprietary
trademarks of Cardiome Pharma Corp.
Aggrastat® and Brinavess® are trademarks
owned by Cardiome and its affiliates worldwide.
Xydalba® is a trademark of Durata Therapeutics Holding
C.V., and used under license.
Zevtera® and Mabelio® are trademarks owned by
Basilea Pharmaceutica International Ltd., and used under
license.
Esmocard® and Esmocard Lyo® are trademarks
owned by Orpha-Devel Handels und Vertriebs GmbH, and used under
license.
Trevyent® is a trademark of SteadyMed and used under
license.
All other trademarks are the property of their respective
owners.
SOURCE Cardiome Pharma Corp.